Ibrutinib (PCI-32765) Mechanism of Action: BTK Inhibition in B-cell Research

Ibrutinib (PCI-32765) MOA:Targeting BTK/BCR Signaling Pathway for Hematological Malignancies

🎯 check Ibrutinib (PCI-32765) product page

Ibrutinib (PCI-32765) is a potent, irreversible covalent BTK inhibitor. It affects BCR and NF-κB signaling pathways by covalently binding to Cys-481 of BTK, effectively inhibiting tumor cell proliferation and inducing apoptosis.

Primary Applications and Mechanism of Action